Lonvoguran ziclumeran (lonvo-z)

Name: Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Generic, brand name and therapeutic class of product
Published: 2026-09-14T15:39:06-04:00

Hereditary angioedema

Also known as NTLA-2002

Manufacturer: Intellia Therapeutics
Regulatory submission: Rolling BLA initiated April 2026 and accepted September 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

2 evidence topics · 2 sources

Manufacturer: Intellia Therapeutics

“Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvo-z” (opens the source at this quote in a new tab)

Manufacturer and product name

“Intellia Therapeutics” (opens the source at this quote in a new tab)
“lonvoguran ziclumeran (“lonvo-z,” also referred to as NTLA-2002)” (opens the source at this quote in a new tab)